Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/89454
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBranford, S.en
dc.contributor.authorRoss, D.en
dc.contributor.authorYeung, D.en
dc.contributor.authorBraley, J.en
dc.contributor.authorHughes, T.en
dc.date.issued2014en
dc.identifier.citationAbstract of power point presentation at 56th ASH Annual Meeting, published in Blood, 2014 / vol.124, iss.21, pp.4561en
dc.identifier.issn0006-4971en
dc.identifier.issn1528-0020en
dc.identifier.urihttp://hdl.handle.net/2440/89454-
dc.description.statementofresponsibilitySusan Branford, David M Ross, David T Yeung, Jodi Braley, and Timothy P. Hughesen
dc.language.isoenen
dc.publisherAmerican Society of Hematologyen
dc.rights© 2014 by The American Society of Hematologyen
dc.source.urihttp://www.bloodjournal.org/content/124/21/4561en
dc.titleAchieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepointen
dc.typeConference itemen
dc.identifier.rmid0030023654en
dc.contributor.conference56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)en
dc.identifier.pubid170566-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS01en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidRoss, D. [0000-0001-7171-2935]en
dc.identifier.orcidHughes, T. [0000-0002-0910-3730]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.